Archive for the ‘Gene Therapy Research’ Category

Cancer Genetics: Implications of Risk Assessment for Risk Reduction
The first cancer susceptibility gene, Rb1, was cloned 25 years ago. Since then, numerous other cancer susceptibility genes have been identified, and clinical testing for many has been incorporated into clinical care. Epidemiologic assessments of cancer risks have led to the development of surveillance strategies. For the more common syndromes, there are ongoing trials assessing various modalities. For the rarer syndromes, recommendations are often extrapolations from existing data on more common conditions. Obtaining support for adequate clinic trials of surveillance and risk reduction strategies for rarer syndromes remain challenging. Understanding of susceptibility gene function should influence the design of intervention trials for risk reduction. The introduction of cancer genomics will clearly affect clinical cancer genetics going forward.From:CPRITTexasViews:0 0ratingsTime:32:22More inScience Technology

See more here:
Cancer Genetics: Implications of Risk Assessment for Risk Reduction - Video

What exactly is a gene?
You #39;ve probably heard about GMOs or Genetically Modified Organisms but what exactly is a gene and what does it mean to modify the genes of a plant or animal? We hear about DNA and genes all the time in the news and in our biology classes but very few of us can actually explain what a gene is? This short film is designed to help. Here we discuss a basic definition of a gene, show what a gene looks like, what it is that genes actually code for, and the basic idea behind Genetically Modified Organisms. The video also briefly mentions one of the ways DNA strongly suggests that all living things are related and share an evolutionary history. Even though the content given here is just a simplified overview of genetics, after watching this video (along with our first video on DNA http://www.youtube.com you should be able to easily follow any news article, basic conversation, or 100 level college course lecture on genetics, even if you #39;ve never taken a biology course or studied genetics in the past. Special thanks to Hip Hop Artist Anthony Danzl for the music http://www.youtube.com Happy 50th to Packy the freckled Elephant from the Portland Zoo. He just had his birthday and was featured in this video (at 0:45) Content for this video has been modified from two text books: Molecular Biology of the Cell, third edition: Bruce Alberts, Dennis Bray, Julian Lewis, Martin Raff, Keith Roberts, James D. Watson Biology Eighth Edition: Neil Campbell, Jane Reece, Lisa Urry, Michael Cain, Steven Wasserman ...From:Stated ClearlyViews:14 0ratingsTime:04:57More inEducation

Originally posted here:
What exactly is a gene? - Video

Accelerated Genetics - Baraboo, WI
Accelerated Genetics 800-451-9275 http://www.yellowbook.com accelerated-genetics-dlkgl8zzw-6083568357.flvFrom:yellowbookViews:0 0ratingsTime:00:36More inHowto Style

Originally posted here:
Accelerated Genetics - Baraboo, WI - Video

Hulk - Trailer
Bruce Banner, a genetics researcher with a tragic past, suffers an accident that causes him to transform into a raging green monster when he gets angry. Director: Ang Lee Writers: Stan Lee (Marvel comic book character), Jack Kirby (Marvel comic book character) Stars: Eric Bana, Jennifer Connelly and Sam ElliottFrom:TheMovieChanneIViews:5 1ratingsTime:01:03More inFilm Animation

Continued here:
Hulk - Trailer - Video

The Genetics Intro
This is our official introduction that will be used in our videos. http://www.facebook.com Further projects and editing will be carried out over time to improve our introduction logo. The logo in this video is protected by copyright, as we are the creators and editors of both the image and special effects in this video. Song Name: All Time Low - Hello BrooklynFrom:stormcrow20k10Views:1 0ratingsTime:00:14More inMusic

Read more:
The Genetics Intro - Video

GENETICS : CF INCIDENCE OF DZ QUESTION
These videos are designed for medical students studying for the USMLE step 1. Feel free to comment and suggest what you would like to see in the future, and I will do my best to fulfill those requests.From:100lyricViews:0 0ratingsTime:02:39More inEducation

Continued here:
GENETICS : CF INCIDENCE OF DZ QUESTION - Video

Sasquatch Researcher Says Bigfoot Ravaged Apple Orchard in his Backyard?
Sasquatch Researcher Says Bigfoot Ravaged Apple Orchard in his Backyard? Like or Follow at ... http://www.facebook.com http://www.twitter.com #mothershouldi A Vermont man insists he spotted Bigfoot in his backyard -- and he says he #39;s got video to prove it. Frank Siecienski of Hubbarton first thought that it was only a deer ravaging the apple orchard that stands on his property last year. "I pointed it out to my wife and she says #39;oh God, #39; the deer must have been hungry," he told WCAX-TV this April. "And I said no, a deer couldn #39;t have eaten that many apples in one night." So the self-described Sasquatch researcher set up a camera to keep watch of what was going on outside. http://www.nydailynews.com I find it suspicious that he is a Sasquatch researcher, and discovers a Sasquatch on his own property.This video was posted on 11/25/2012. Then, today (11/26/2012), I find this article: #39;Bigfoot #39; DNA Sequenced In Upcoming Genetics Study http://www.prweb.com This video uses copyrighted material in a manner that does not require approval of the copyright holder. It is a fair use under copyright law.Copyright Disclaimer Under Section 107 of the Copyright Act 1976, allowance is made for fair use for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. Fair use is a use permitted by copyright statute that might otherwise be infringing. Non-profit, educational or personal use tips the balance in favor of fair use.From:MotherShouldIViews:0 0ratingsTime:01:25More inEducation

Link:
Sasquatch Researcher Says Bigfoot Ravaged Apple Orchard in his Backyard? - Video

DNA Genetics At the 25th Cannabis cup
From:ShrillMillViews:3 0ratingsTime:21:50More inGaming

Continue reading here:
DNA Genetics At the 25th Cannabis cup - Video

BAMF Bombs in Amsterdam High Times Cannabis Cup
The PotCast visits Amsterdam for the 25th High Times Cup. They are gathered at the Cali Connection booth dabbing on some Solventless Lemon Og made by BAMF of BAMF Extractions and Selecta Nikka T from Essential Extractions. West Coast Concentrates, MTG Seeds, Rare Dankness, DabTools, The Digger, OG Genetics were also on scene. Check out this epic moment in PotCast history! PC420.comFrom:stingystonerViews:3 2ratingsTime:03:42More inComedy

View post:
BAMF Bombs in Amsterdam High Times Cannabis Cup - Video

External Thrombosed Hemorrhoids and What You Can Do Today
http://www.HemRid.com External Thrombosed Hemorrhoids and What You Can Do What are external thrombosed hemorrhoids and how can you get fast and powerful relief? External thrombosed hemorrhoids occur when an external hemorrhoids becomes strangulated. The hemorrhoid will form a clot because the blood pools within the hemorrhoid as a result of being strangulated. Diet and exercise play a key role in how likely and often you will have hemorrhoids. Age, pregnancy, and genetics are also factors too. If you think that you may have hemorrhoids you should consult your doctor. http Please visit http://www.HemRid.com for more information on external thrombosed hemorrhoids surgery, external thrombosed hemorrhoids removal, external thrombosed hemorrhoids treatment, and external thrombosed hemorrhoids symptoms.From:hemridvideosViews:2 0ratingsTime:01:42More inEducation

See more here:
External Thrombosed Hemorrhoids and What You Can Do Today - Video

Newswise BETHESDA, MD -- November 26, 2012 -- The Genetics Society of America (GSA) is pleased to announce the selection of two early career scientists, graduate student Kathleen Dumas (University of Michigan, Ann Arbor) and postdoctoral researcher Krista Dobi, PhD (Memorial Sloan-Kettering Cancer Center, New York), as advisory representatives to the GSA Board of Directors. These two individuals were selected from among more than 50 of GSAs graduate student and postdoctoral members who volunteered to serve in leadership positions on the GSA Board of Directors. Additional early career researchers will be selected to contribute to the work of GSA committees.

GSA has a long history of supporting its early career members through programs and policies that promote the professional development of our student and postdoc members, said GSA President Phil Hieter, PhD. The selection of Kathleen and Kristaand their peers on our committeeswill ensure that the next generation of geneticists will always be at the table when Society priorities are discussed.

GSA Executive Director Adam Fagen, PhD, added that we hope this is just the beginning of more active engagement of our early career members in the work of the Society. Students and postdoctoral scholars represent nearly half of GSAs 5,000 members.

Ms. Dumas is a graduate student in the Cell and Molecular Biology Department at the University of Michigan (UM), Ann Arbor, working on insulin signaling genetics in the nematode worm C. elegans and also completed a graduate certificate program in Science, Technology, and Public Policy. Her research success has been facilitated by what she expressed as the collaborative environment among C. elegans researchers. Ms. Dumas has a history of volunteer service to her professional community, which includes serving as co-president of the Graduate Student Council at UM; revitalizing a moribund chapter of the Association for Women in Science; and serving as a lead organizer for a forum for graduate students and postdoctoral fellows to share research, gain interdisciplinary perspectives and network with experts in the science and policy fields. Ms. Dumas has attended several International C. elegans meetings organized by GSA and received a 2012 GSA DeLill Nasser Travel Award for Professional Development in Genetics.

Katie Dumas is a sophisticated student researcher who has exceptional leadership skills and dedication to bridging the interface between research and public policy, said Jessica Schwartz, PhD, Director of the PhD Program in Cell & Molecular Biology at UM. She is an excellent communicator and will represent an informed student perspective effectively. I am certain that Katie will make excellent contributions to GSA, she added.

I am honored and excited to serve as the inaugural advisory graduate student representative to the GSA Board of Directors, said Ms. Dumas. I believe the Societys commitment to embracing the perspectives of its graduate student constituents exemplifies its mission to support the next generation of geneticists.

Dr. Dobi, a postdoctoral researcher in developmental biology at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City, is studying the development of muscles in the fruit fly Drosophila melanogaster. As a graduate student she studied gene regulation in the yeast Saccharomyces cerevisiae. Not only does she have varied and rich research experiences, according to her MSKCC postdoctoral mentor Mary Baylies, PhD, Dr. Dobi is an effective and clear communicator, an excellent mentor, and she has excellent organizational and leadership abilities. She has mentored high school, undergraduate and graduate students, served on advisory committees and organized conferences. While an undergraduate at Princeton, she also served as executive director of the Princeton Model Congress, planning a conference in Washington, D.C. for 1,000 high school students and their teachers. Dr. Dobi has attended GSA-sponsored Drosophila research conferences and received a 2012 GSA DeLill Nasser Travel Award for Professional Development in Genetics.

As a yeast and Drosophila geneticist, I am truly honored to be the first postdoctoral representative to the GSA Board of Directors, said Dr. Dobi. I look forward to sharing the perspectives and concerns of early-career scientists with the Board, and to working with them to advance the field of genetics.

ABOUT GSA: Founded in 1931, the Genetics Society of America (GSA) is the professional membership organization for scientific researchers, educators, bioengineers, bioinformaticians and others interested in the field of genetics. Its nearly 5,000 members work to advance knowledge in the basic mechanisms of inheritance, from the molecular to the population level. The GSA is dedicated to promoting research in genetics and to facilitating communication among geneticists worldwide through its conferences, including the biennial conference on Model Organisms to Human Biology, an interdisciplinary meeting on current and cutting edge topics in genetics research, as well as annual and biennial meetings that focus on the genetics of particular organisms, including C. elegans, Drosophila, fungi, mice, yeast, and zebrafish. GSA publishes GENETICS, a leading journal in the field and an online, open-access journal, G3: Genes|Genomes|Genetics. For more information about GSA, please visit http://www.genetics-gsa.org. Also follow GSA on Facebook at facebook.com/GeneticsGSA and on Twitter @GeneticsGSA.

Go here to see the original:
Early Career Scientists Will Advise Genetics Society of America's Board

SAN MARINO, Calif.--(BUSINESS WIRE)--

Viral Genetics, Inc. (OTC Pink: VRAL) today announced that it has changed its name to VG Life Sciences Inc. and that it has completed its 1-for-600 reverse stock split, both of which will take effect at the open of trading on November 27, 2012. As of November 27, 2012, shares of the Companys common stock will begin trading on a split-adjusted basis on the OTC Pink market under the symbol VRAL with the fifth character D added to the end of the trading symbol for a period of 20 business days after November 27, 2012 to indicate the reverse stock split has occurred. Thereafter, the Companys symbol will revert to its original symbol VRAL until January 10, 2013. Effective January 10, 2013, a new ticker symbol for the Company will be announced and thereafter will take effect.

As previously disclosed, on November 27 every six hundred shares of outstanding Viral Genetics, Inc. common stock will be automatically combined into one share of VG Life Sciences Inc. common stock without any change in the par value per share. This change reduced the number of outstanding shares of common stock from approximately 1.9 billion to approximately 3.2 million. No fractional shares were issued in connection with the reverse stock split.

About VG Life Sciences Inc.

San Marino, California-based VG Life Sciences Inc., formerly known as Viral Genetics, discovers and develops drug therapies from two exclusively licensed platform technologies based on over 60 patents: Metabolic Disruption (MDT) and Targeted Peptides (TPT). A physician-initiated Phase I clinical trial of an MDT compound in combination with Nexavar on Stage III and IV ovarian cancer patients is ongoing at the Cancer Therapy and Research Center of The University of Texas Health Science Center at San Antonio. A majority-owned subsidiary, VG Energy (www.vgenergy.net), is dedicated to exploring biofuel and agricultural applications for the MDT platform. Founded in 1994, the biotech company is researching treatments for drug-resistant cancer, Lyme disease, Strep, Staph and Sepsis, and HIV/AIDS. For more information, visit http://www.viralgenetics.com.

About VG Energy

VG Energy, Inc. is an alternative energy and agricultural biotech company that is a majority-owned subsidiary of VG Life Sciences Inc. VG Energy holds the exclusive worldwide license to the Metabolic Disruption Technology (MDT) patent rights for use in the increase of production of various oils from algae, plants and seeds. VG Energys pivotal discoveries are expected to facilitate the biofuel industry in overcoming its major obstacle in the area of production efficiency, thereby leading to an increase in production yields that generate economically viable returns on investment, allowing renewable biodiesel to be competitive with fossil fuels. For more information, please visit http://www.vgenergy.net.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals and other risks described by VG Life Sciences Inc. from time to time in its periodic reports, including statements about its subsidiary, VG Energy, Inc. None of VG Life Sciences Inc.s drug compounds are currently approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world, nor are any non-pharmaceutical products of VG Energy, Inc. commercialized. While VG Life Sciences Inc. believes that the forward-looking statements and underlying assumptions are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of VG Life Sciences Inc. to establish the efficacy of any of its drug therapies in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of those drug compounds in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, the successful outcome of such studies or tests, or the successful commercialization of VG Energy, Inc.s non-pharmaceutical products. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by VG Life Sciences Inc. or any other person that the objectives and plans of VG Life Sciences Inc. will be achieved. VG Life Sciences Inc. disclaims any obligation to update these forward-looking statements, except as required by law.

Read the rest here:
Viral Genetics, Inc. Announces Corporate Name Change to VG Life Sciences Inc. and Reverse Stock Split Effective ...

Newswise The Genetics Society of America (GSA) welcomes six new members elected by the general membership to the 2013 GSA Board of Directors. The new members include a vice president, secretary and four directors. They are: Vicki L. Chandler, PhD (Gordon and Betty Moore Foundation). Dr. Chandler will serve as vice president in 2013 and as GSA president in 2014. Anne M. Villeneuve, PhD (Stanford University School of Medicine). Dr. Villeneuve will serve as secretary beginning 2013. Lynn Cooley, PhD (Yale University), director. Anna Di Rienzo, PhD (University of Chicago), director. Sarah C. R. Elgin, PhD (Washington University in St. Louis), director. Deborah A. Siegele, PhD (Texas A&M University), director.

As always, GSA is fortunate to be able to call upon such talented individuals to provide leadership for the Society, said GSA Executive Director Adam P. Fagen, PhD. As we welcome these new leaders, we thank the outgoing Board members for their years of dedicated service to GSA,

These new officers and directors began their tenure on January 1, 2013, and will remain on the GSA Board until December 31, 2015.

New Members of the GSA Board of Directors

Vice President (and President-Elect): Vicki L. Chandler, PhD, Chief Program OfficerScience, Gordon and Betty Moore Foundation, Palo Alto, CA.

Dr. Chandler is a plant geneticist and a long-time GSA member, who has served as an editor of the GSA journal GENETICS and as a member of the GSA Board in the 1990s. Her research on paramutation, an epigenetic process, has implications not only for maize, which she used in her research, but also for animal and human genetics and genetic diseases. For most of the last decade, Dr. Chandler has built bridges between the genetic worlds of plants and animals and developed a number of lasting scientific partnerships. From 2004-2009, she was director of the BIO5 Institute, an interdisciplinary research center at the University of Arizona, while her own lab worked on maize and other plants as models of genetic effects and applied findings to the study of human biology. At the Gordon and Betty Moore Foundation, Dr. Chandler helps foster scientific partnerships and the development of new technologies. In her new role as Vice President of GSA, she says, GSA has an obligation to communicate through public outreach and education, advances in genetics that offer significant potential improvements in health, energy, food and the environment, but also raise personal and social issues. Dr. Chandler is a member of the National Academy of Sciences and a Fellow of the American Association for the Advancement of Science; she is also a Searle Scholar and Presidential Young Investigator and received a National Institutes of Health (NIH) Directors Pioneer Award. Dr. Chandler served as president of the American Society of Plant Biologists in 2002.

Secretary: Anne M. Villeneuve, PhD, Professor of Developmental Biology and Genetics, Department of Developmental Biology, Stanford University School of Medicine, Stanford, CA.

A developmental geneticist, Dr. Villeneuve studies the mechanisms of chromosome inheritance in eukaryotes during meiosis, using the nematode worm C. elegans for much of her work. She has been a member of GSA for many years and has participated in many GSA-sponsored conferences, has served as an associate editor of GENETICS, and has published some of her most influential articles in the Journal. She has an abiding, vested interest in promoting and sustaining the crucial mission of GSA, which includes being an advocate for support of basic science research and continued government support for crucial resources such as the genetics stock centers and databases that are essential to sustain ongoing research. She received a Junior Faculty Scholar Award from the Howard Hughes Medical Institute and was named a Searle Scholar.

Directors: Lynn Cooley, PhD, C.N.H. Long Professor of Genetics; Professor of Cell Biology and Molecular, Cellular & Developmental Biology, Yale University, New Haven, CT.

Dr. Cooley studies egg development or oogenesis, using the fruit fly Drosophila melanogaster as a model system. Specifically, her lab focuses on the cellular mechanisms controlling egg growth, which, according to her laboratory website, are directly relevant to female fertility in other animals, including humans. She is an associate editor of the GSA journal GENETICS, and has been a member of GSA for many years. She is also an active member of the Drosophila genetics community, including serving as an organizer for the GSA-sponsored Annual Drosophila Research Conference in 2009. As a member of the GSA Board of Directors, Dr. Cooley is looking forward to supporting GSAs incredibly important advocacy effort to maintain government support for basic research in these times of tight federal budgets. She received a Damon RunyonWalter Winchell Cancer Fund Postdoctoral Fellowship and was named a Pew Scholar in the Biomedical Sciences.

See the original post here:
Genetics Society of America Welcomes 2013 Board Members

BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) announced today that ADCETRIS (brentuximab vedotin) has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of mycosis fungoides (MF). MF is the most common type of cutaneous T-cell lymphoma (CTCL). Seattle Genetics and its ADCETRIS collaborator, Millennium: The Takeda Oncology Company, are conducting the ALCANZA trial, a phase III clinical trial of ADCETRIS for patients with CD30-positive relapsed CTCL, including MF. ADCETRIS is not approved for the treatment of CTCL.

This orphan drug designation is a part of our ADCETRIS regulatory strategy, designed to complement the Special Protocol Assessment for the ongoing ALCANZA study, said Clay B. Siegall, President and Chief Executive Officer of Seattle Genetics. The encouraging data from investigator-sponsored trials of ADCETRIS in CTCL, which will be presented at ASH, provide further support for our activities in this patient population.

FDA orphan drug designation is intended to encourage companies to develop therapies for the treatment of diseases that affect fewer than 200,000 individuals in the United States. This designation provides Seattle Genetics with the opportunity for seven years of marketing exclusivity, grant funding to defray costs of clinical trial expenses, tax credits for clinical research expenses and potential waiver of the FDA's application user fee.

The ALCANZA trial is a randomized phase III clinical trial of ADCETRIS for relapsed CD30-positive CTCL patients. The trial is assessing ADCETRIS versus investigators choice of methotrexate or bexarotene in patients with CD30-positive CTCL, including those with primary cutaneous anaplastic large cell lymphoma (pcALCL) or MF. The primary endpoint of the study is overall response rate lasting at least 4 months. Approximately 124 patients will be enrolled in the pivotal trial. The ALCANZA trial is being conducted under a Special Protocol Assessment agreement from the FDA. The study also received European Medicines Agency scientific advice. For more information about the ALCANZA trial, visit http://www.clinicaltrials.gov.

At the 54th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA, data from two investigator-sponsored trials of ADCETRIS in CTCL will be reported:

Brentuximab vedotin demonstrates significant clinical activity in relapsed or refractory mycosis fungoides with variable CD30 expression (Abstract #797)

Results of a phase II trial of brentuximab vedotin (SGN-35) for CD30-positive cutaneous T-cell lymphomas and lymphoproliferative disorders (Abstract #3688)

About ADCETRIS

ADCETRIS (brentuximab vedotin) is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

More here:
Seattle Genetics Receives FDA Orphan Drug Designation for ADCETRIS® (Brentuximab Vedotin) in Mycosis Fungoides

FATAL FAMILIAL INSOMNIA BIO PSA
The question for my presentation that I was looking for an answer to was "What treatments have been discovered to fight or cure Fatal Familial Insomnia?" In my research I found that there has been some treatments tested on mice models that have slowed down the deadly disease, but researchers have not found one that will completely cure or sufficiently fight Fatal Familial Insomnia. In my discussion I talk about when the disease was discovered and how rare it is. I also explain what a prion disease is and codon is being effected. I have a chart in my presentation that compares the different sleep spindles, normal sleep vs. FFI sleep, so that the viewer can understand how extremely different a person with FFI sleep stages are to some one with normal sleep functions. The majority of my presentation was focused on the treatments section in which I list the tested treatments, some examples of cases that I found, and whether they made a difference or not. I found out that sleeping medications are the least successful in helping patients with FFI and can actually worsen the condition. Gene therapy as we discussed in the course already is the replacement of a mutated gene with a repaired one. The findings from the gene therapy case and agomelatine case showed that they are a helpful treatment, but not the cure to FFI. Even though these treatments did not work sufficiently to cure FFI, I think they are leading the researchers in the right direction to actually find the cure.From:DMarie23ifyViews:0 0ratingsTime:05:23More inPeople Blogs

Continued here:
FATAL FAMILIAL INSOMNIA BIO PSA - Video

Introduction To Stem Cell Therapy For Parkinson #39;s And Alzheimer #39;s Diseases | Stem Cell Malaysia
stemcellmalaysia.com Stem cell therapy projects so much potential and hope for patients of different illnesses. This is due to the unique characteristics of stem cells. For more information on stem cell therapy, please visit Stem Cell Malaysia at stemcellmalaysia.comFrom:stemcells2012Views:5 1ratingsTime:03:51More inPeople Blogs

Go here to see the original:
Introduction To Stem Cell Therapy For Parkinson's And Alzheimer's Diseases | Stem Cell Malaysia - Video

Introducing Stem Cell Therapy Using Oral Placenta Stem Cells | Stem Cell Malaysia
stemcellmalaysia.com Stem cell therapy can take on various forms and choices. Due to the advent of technology, stem cell therapy using oral placenta stem cells is now available. For more information on stem cell therapy, please visit Stem Cell Malaysia at stemcellmalaysia.comFrom:stemcells2012Views:3 1ratingsTime:05:23More inScience Technology

Read more:
Introducing Stem Cell Therapy Using Oral Placenta Stem Cells | Stem Cell Malaysia - Video

DWAH Stem Cell Therapy.
From:Dundas West AHViews:6 0ratingsTime:03:53More inPets Animals

View post:
DWAH Stem Cell Therapy. - Video

Perrin 410 Animal Hospital Stem Cell Therapy
From:perrin410Views:0 0ratingsTime:09:58More inPets Animals

Continue reading here:
Perrin 410 Animal Hospital Stem Cell Therapy - Video

PROVO -- Alzheimer's kills. First, it eats the minds of its victims, leaving them with nothing more than the scraps of memories. Then, when there's nearly nothing left, it takes the sufferer's life.

But new research from Brigham Young University and several other universities shows how researchers are fighting back to kill the common disease.

The study argues that people with a rare variant of a gene are significantly more likely to develop Alzheimer's disease at some point in their lives. It relied on genetic information from more than 25,000 people and was a collaboration between BYU, University College London, Washington University and the National Institutes of Health, among other institutions.

At BYU, geneticist John Keoni Kauwe explained that the gene in question -- officially called TREM2 -- normally regulates immune system responses in the brain. When it gets damaged, it may increase a person's risk of developing Alzheimer's disease "between two and sixfold."

"It has just huge effects on risk," Kauwe added.

Kauwe explained the concept by comparing genetics to a new recipe book that might get ruined if actually used in the kitchen. Rather than mess up the book, he pointed out, a chef might make a photocopy.

"DNA is made into RNA, which is kind of like taking a nice photo copy of your recipe book," he said.

The RNA then gets made into a protein, Kauwe said, which is like the final cake the cook might have made from the original recipe. Except that in some cases, a person's genes produce an "Alzheimer's cake," or a set of genes with a variant that dramatically increases risk of developing the disease.

"Some people carry a version of this gene that doesn't work very well," he said.

According to Kauwe, knowing about the gene should make it easier and more accurate to predict if a person is likely to get Alzheimer's disease. He said the variant gene is present in about 1 percent of Alzheimer's cases, which means a lot of actual people with the disease.

Follow this link:
BYU research identifies gene that increases Alzheimer's risk

What A PIECE OF CRAP - DECEIVER - I AM SO SICK OF THESE PEOPLE!
The latest lie from the pit of hell = "It is written that a group of individuals -- called the Elohim -- made man with a genetic engineering intervention, by mixing their own DNA with the DNA of primates already present on the Earth" beforeitsnews.comFrom:Susan KimballViews:14 1ratingsTime:02:21More inEducation

Excerpt from:
What A PIECE OF CRAP - DECEIVER - I AM SO SICK OF THESE PEOPLE! - Video

Ray X-Spex - Day The World Turned Day-Glo Genetic Engineering @ The Royal Oak, Bath 18-10-2012
The Royal Oak Cider and Punk weekend Public event · By The Royal Oak, Bath 18 October at 16:00 until 20 October at 01:00 http://www.facebook.com Thats correct it time for another punk and cider weekend, i mean what could go wrong with over 30 strange and lovely ciders to try, Lots of lovely live music and as always its FREE entry. There will also be a chance to get some vintage B,O,B festival merchandise and rase money for the 2013 B,O,B festival. For more information on B,O,B fest visit http://www.thebobfestival.com MUSIC: Thursday = This Ends Hear, The Lone Sharks and Ray X Spex. Friday = The SetBacks, The Kiss Curis, Virus, Rita Lynch and Citizen Fish. Saturday = Onanism, Lower The Flag, Cydernide and The A Heads.From:MalcolmHerrsteinViews:10 0ratingsTime:06:19More inMusic

Excerpt from:
Ray X-Spex - Day The World Turned Day-Glo

Genetic engineering The world #39;s greatest scam flash
From:Kai KuangViews:3 0ratingsTime:03:51More inPeople Blogs

Originally posted here:
Genetic engineering The world's greatest scam flash - Video

Universal Genetic Engineering Insanity (HD)
Twitter twitter.com twitter.com twitter.com * World News * News Today * Latest news * Breaking * Breaking News * Thank you for watching!From:MatrixVIVAViews:0 0ratingsTime:10:08More inNews Politics

Read the original:
Universal Genetic Engineering Insanity (HD) - Video

Stardust Planet X Objects
Maverick physicist James McCanney returned to discuss the Stardust mission as well as the many Planet X-type objects in the solar system. We don #39;t have enough astronomical data or equipment to detect or pinpoint the orbits of such Planet X bodies, he declared, but the larger ones may travel with entourages that include comets. Sources such as the Kolbrin Bible describe ancient catastrophes that McCanney associates with the passage of these objects, which he estimates have neared Earth around five times in the last 10000 years. Undoubtedly, we #39;ll be faced with the arrival of one of these objects again, he said, arguing that our time and resources should be focused on making large segments of the population spacefaring, so that humanity could survive a potential extinction event. He envisions hundreds of tubes bundled together as rotating cities that propel themselves out into space. Though he lauded the engineering success of the Project Stardust mission, McCanney expressed concern over possible contamination and viral danger from the retrieved particles and recommended that the materials be handled at a space lab instead. Richard C. Hoagland phoned in briefly, suggesting that NASA may have secretly swapped out the particles at the Utah landing site. Stardust Prophecy Appearing during the second half of the first hour, author William Henry shared his mythological interpretation of project Stardust. He believes the NASA mission may have prophetic implications, and that ...From:DiscloseTruthTVViews:10 1ratingsTime:01:17:48More inEducation

Read more:
Stardust